Again,activation of the ERK1/2 pathway was a negative biomarker for glioblastoma,renal, pancreatic, gastric, bladder, lung adenocarcinoma, and squamous cellcarcinoma of the lung. Here, MAPK3 is linked to lung adenocarcinoma.